Creatine Kinase MB (CK-MB); Contaminants: <2% LD

Creatine Kinase MB (CK-MB) is known to exist in two forms: CK-MB2, the gene product, and CK-MB1, which is modified upon release into the bloodstream. Carboxypeptidase cleavage of the C-terminal lysine residue of the M subunit transforms CK-MB2 into CK-MB1. In healthy individuals, CK-MB2 is in equilibrium with the modified CK-MB1 subform at a ratio of approximately 1:1. In the early hours of myocardial infarction, the abrupt release of CK-MB2 from myocardium produces an upward shift in the serum CK-MB2/CK-MB1 ratio, usually before total CK-MB (CK-MB2 + CK-MB1) exceeds normal levels. While assays for serum levels of total CK-MB have long been used to aid in the diagnosis of myocardial infarction, determinations of the serum CK-MB2/CK-MB1 ratio are also proving useful.

This preparation of CK-MB is isolated from human heart muscle and is provided as a liquid in 5mM Sodium Succinate, 10mM Sodium Chloride, 1mM EDTA, 5mM β-Mercaptoethanol, 50% Glycerol, pH 7.0 ± 0.1.

Note: This product is not packaged by mass (e.g., mg), but by the unit. One unit is defined as that amount of enzyme required to convert 1 μmole of creatine phosphate to creatine per minute at an assay temperature of 37°C.

Companion Products:

• CK-MB Monoclonal Antibodies (2 clones)